Thienopyridine derivatives such as clopidogrel have been shown to reduce the incidence of death in patients undergoing percutaneous coronary intervention when used in conjunction with aspirin. Recently, a new thienopyridine, prasugrel, significantly reduced the primary endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke to 9.9% compared to 12.1% for clopidogrel...

ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372:537–546. 37. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 1999;138:1–5. 38. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukoc...

RESEARCH DESIGN AND METHODSdThe current study was conducted using the computerized database of the Sharon-Shomron District of Clalit Health Services in Israel. Included in the study were subjects 65 years of age and above with new-onset DM. The primary outcome measures were all-cause mortality and coronary revascularization procedures with either percutaneous coronary intervention or coronary a...

INTRODUCTION AND OBJECTIVES The aim of this study was to analyze the prevalence, risk factors, and short- and long-term prognosis of patients with acute coronary syndrome and normal renal function who developed percutaneous coronary intervention-associated nephropathy. METHODS This was an observational, retrospective, single-center study with a prospective follow-up of 470 consecutive patient...